Literature DB >> 8907130

Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics.

G Hasenfuss1, B Pieske, B Kretschmann, C Holubarsch, N R Alpert, H Just.   

Abstract

Calcium sensitizers may influence myocardial energetics by their action on calcium turnover and on crossbridge behavior. Using a myothermal method, the effects of the Ca2+ sensitizer EMD-53998 on calcium cycling, crossbridge behavior, and myocardial energy turnover were compared with the effects of an increase in extracellular calcium from 1.25 to 7.5 mM and with the effects of the catecholamine isoproterenol. All three inotropic interventions increased isometric force development in right ventricular rabbit papillary muscles. Relaxation time was decreased with isoproterenol, unchanged with high calcium, and increased with EMD 53998. Calcium cycling-related energy consumption, as measured by tension-independent heat, increased by 234% with high calcium, by 439% with isoproterenol, and by 77% with EMD 53998. In contrast to high calcium and isoproterenol, EMD 53998 increased economy of crossbridge cycling by increasing the force-time integral of the individual crossbridge cycle. The data indicate that EMD 53998 acts by phosphodiesterase inhibition and myofilament calcium sensitization. The latter effect is in part mediated by alteration of crossbridge behavior. Because of its effects on calcium cycling and crossbridge function myocardial energy turnover was reduced significantly with EMD 53998, whereas energy turnover was unchanged with high calcium and was increased with isoproterenol. The new calcium sensitizer levosimendan was investigated in isolated failing human myocardium. Levosimendan dose-dependently increased isometric tension. The inotropic effect was associated with increased rate of relaxation and reduced relaxation time. Measurements of intracellular calcium using the photoprotein aequorin suggest that levosimendan acts by increasing myofilament calcium sensitivity and by increasing cAMP due to phosphodiesterase inhibition. However, the contribution of the cAMP system to the action of levosimendan appears to be rather small. Therefore, the finding of a positive lusitropic effect of levosimendan may be consistent with the notion that levosimendan binds to troponin-C and increases calcium sensitivity only at high (systolic) intracellular calcium concentrations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8907130

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

Review 1.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Calcium sensitising agents in heart failure.

Authors:  L Mathew; S D Katz
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

3.  The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts.

Authors:  Matthias Behrends; Jürgen Peters
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

Review 4.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  [Levosimendan. Clinical indications of a new vasoactive substance].

Authors:  J-P Braun; U Döpfmer; M Kastrup; I Roots; A Borges; M Schneider; P Dohmen; W Kox; C Spies
Journal:  Anaesthesist       Date:  2004-02       Impact factor: 1.041

6.  Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.

Authors:  Elmir Omerovic; Truls Råmunddal; Per Albertsson; Mikael Holmberg; Per Hallgren; Jan Boren; Lars Grip; Göran Matejka
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

7.  Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts.

Authors:  Shuhei Matsumoto; Sungsam Cho; Shinya Tosaka; Ushio Higashijima; Takuji Maekawa; Tetsuya Hara; Koji Sumikawa
Journal:  Cardiovasc Diabetol       Date:  2012-01-12       Impact factor: 9.951

Review 8.  A review of levosimendan in the treatment of heart failure.

Authors:  Hulya Akhan Kasikcioglu; Nese Cam
Journal:  Vasc Health Risk Manag       Date:  2006

9.  Effects of the NO donor sodium nitroprusside on oxygen consumption and energetics in rabbit myocardium.

Authors:  Mark Hünlich; Gerd Hasenfuss
Journal:  Basic Res Cardiol       Date:  2009-02-03       Impact factor: 17.165

10.  The effect of levosimendan on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats.

Authors:  Hasan Ali Kiraz; Fatih Poyraz; Gülay Kip; Özlem Erdem; Metin Alkan; Mustafa Arslan; Abdullah Özer; Volkan Şivgin; Faruk Metin Çomu
Journal:  Libyan J Med       Date:  2015-01       Impact factor: 1.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.